

MIFlowCyt: The Minimum Information About a Flow Cytometry Experiment

Jamie A. Lee,^{1†} Josef Spidlen,^{2†} Keith Boyce,³ Jennifer Cai,¹ Nicholas Crosbie,⁴ Mark Dalphin,⁵ Jeff Furlong,⁶ Maura Gasparetto,² Michael Goldberg,⁷ Elizabeth M. Goralczyk,⁸ Bill Hyun,⁹ Kirstin Jansen,⁶ Tobias Kollmann,¹⁰ Megan Kong,¹ Robert Leif,¹¹ Shannon McWeeney,^{12,13,14} Thomas D. Moloshok,⁸ Wayne Moore,¹⁵ Garry Nolan,¹⁶ John Nolan,¹⁷ Janko Nikolich-Zugich,¹⁸ David Parrish,³ Barclay Purcell,¹⁹ Yu Qian,¹ Biruntha Selvaraj,¹⁹ Clayton Smith,² Olga Tchuvatkina,⁷ Anne Wertheimer,²⁰ Peter Wilkinson,²¹ Christopher Wilson,⁶ James Wood,²² Robert Zigon,²³ The International Society for Advancement of Cytometry Data Standards Task Force, Richard H. Scheuermann,^{1,24} Ryan R. Brinkman^{2*}

¹Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390

²Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3

³Immune Tolerance Network, Pittsburgh, Pennsylvania 15238

⁴Invai Technologies, Mentone 3194, Victoria, Australia

⁵Amgen Inc., Thousand Oaks, California 91320

⁶Department of Immunology, University of Washington, Seattle, Washington 98195

⁷BD Biosciences, San Jose, California 95131

⁸Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

⁹Laboratory for Cell Analysis, University of California, San Francisco, California 94143-0808

¹⁰Vaccine Evaluation Center, Child and Family Research Institute, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4H4

¹¹Newport Instruments, San Diego, California 92115

• Abstract

A fundamental tenet of scientific research is that published results are open to independent validation and refutation. Minimum data standards aid data providers, users, and publishers by providing a specification of what is required to unambiguously interpret experimental findings. Here, we present the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) standard, stating the minimum information required to report flow cytometry (FCM) experiments. We brought together a cross-disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop the standard. The standard was subsequently vetted by the International Society for Advancement of Cytometry (ISAC) Data Standards Task Force, Standards Committee, membership, and Council. The MIFlowCyt standard includes recommendations about descriptions of the specimens and reagents included in the FCM experiment, the configuration of the instrument used to perform the assays, and the data processing approaches used to interpret the primary output data. MIFlowCyt has been adopted as a standard by ISAC, representing the FCM scientific community including scientists as well as software and hardware manufacturers. Adoption of MIFlowCyt by the scientific and publishing communities will facilitate third-party understanding and reuse of FCM data. © 2008 International Society for Advancement of Cytometry

• Key terms

immunology; fluorescence-activated cell sorting; knowledge representation

FLOW cytometry (FCM) systems have been available to investigators for over 30 years, and the field continues to advance at a rapid rate. FCM has been responsible for major progress in basic and clinical research by enabling the phenotypic and functional characterization of individual cells in a high-throughput manner. Advances in the technology now allow for automated, multiparametric analyses of thousands of samples per day (1). Each data set can consist of multidimensional descriptions of millions of individual cells, producing data similar in size and complexity to gene expression microarrays. Like the microarray field, the ability to collect FCM data is outpacing the computational means for data handling and analysis. Furthermore, the lack of reporting standardization limits collaboration, independent validation/refutation, and meta-analysis, and thus minimizes the value of the wealth

¹²OHSU Cancer Institute, Oregon Health and Science University, Portland, Oregon 97006

¹³Division of Biostatistics, Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon 97006

¹⁴Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon 97006

¹⁵Genetics Department, Stanford University School of Medicine, Stanford, California 94305

¹⁶Department of Microbiology and Immunology, Stanford University, Stanford, California 94305

¹⁷La Jolla Bioengineering Institute, La Jolla, California 92037

¹⁸Department of Molecular Microbiology and Immunology, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon 97006

¹⁹Cytopeia Incorporated, Seattle, Washington 98125

²⁰Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon 97006

²¹University of Montreal, Montreal, Québec, Canada H3C 3J7

²²Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157

²³Beckman Coulter, Inc., 7451 Winton Drive, Indianapolis, Indiana

²⁴Division of Biomedical Informatics, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Received 29 May 2008; Accepted 10 July 2008

Additional Supporting Information may be found in the online version of this article.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health.

[†]The first two authors contributed equally to this work.

Grant sponsor: National Institute of Biomedical Imaging and Bioengineering, NIH; Grant number: EB005034; Grant sponsor: NIAID Bioinformatics Integration Support Contract (BISC); Grant number: AI40076.

*Correspondence to: Ryan R. Brinkman; Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada V5Z 1L3

Email: rbrinkman@bccrc.ca

Published online 27 August 2008 in Wiley InterScience (www.interscience.wiley.com)

DOI: 10.1002/cyto.a.20623

© 2008 International Society for Advancement of Cytometry

of existing FCM data because of poor annotation (2). Such technological advances, in the absence of reporting standards, also introduce considerable challenges for the producers, reviewers, and consumers of today's biomedical and immunology literature (3).

To address these shortcomings, we have brought together a cross-disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop a minimum information reporting standard for FCM. This large collaborative group proposed the initial version of the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt). The proposal underwent several stages of consultations by the International Society for Advancement of Cytometry (ISAC) Data Standards Task Force (DSTF), which has been responsible for all FCM-related standards for the past 30 years, such as the FCS (4) data file standard. MIFlowCyt was further reviewed by the broader scientific community and finally approved by the ISAC DSTF, ISAC Data Standards Committee, and recently adopted as an ISAC standard by the ISAC Council. MIFlowCyt is also endorsed by the Data Interoperability Steering Committee of the Division of Allergy, Immunology, and Transplantation within the National Institute of Allergy and Infectious Diseases (NIAID), which strongly supports the use of MIFlowCyt and related data format standards.

RESULTS

Design Principles

Throughout the biomedical sciences, minimum information checklists are beginning to find favor with scientists, pub-

lishers, and funders alike. Such checklists ensure that descriptions of methods, resulting data, and analyses support the unambiguous interpretation, corroboration, and reuse of data (5). As emphasized by several cross-community integration efforts, e.g., FuGE (6), MIBBI (5), OBI (7), most biological and biomedical investigations have similar design patterns. Typically, they are driven by a hypothesis or purpose, which guides the experimental design. Samples or specimens are prepared and reagents are used to evaluate analytes within the samples. Data are acquired using instruments, followed by data processing and analysis to interpret and conclude the experiment.

To simplify cross-domain comparison and integration, the required minimum information specified by MIFlowCyt (see Supplementary Material) is organized similarly to minimal information requirements for other MIBBI-registered high-throughput biological experiments, i.e., organizing the information by experiment overview, sample/specimen description, instrument details, and data analysis (Table 1). The organization of MIFlowCyt does not specify the order or format in which experiment annotation should be provided, and MIFlowCyt is not intended to replace any additional information already collected within any particular group. The actual information is expected to come from several sources. Research scientists provide detailed information about the experiment overview and design, information about the samples used in the experiment including preparation, treatment, and staining details, and details about data analysis procedures. FCM instruments are expected to provide details about configuration and settings and analytical software details relevant to performed analyses. An example of a MIFlowCyt-com-

Table 1. Components of a MIFlowCyt-compliant experiment description

Experiment overview	Purpose/goal/hypothesis Experiment variables Conclusions Quality control
Flow sample (specimen)	Material Source/organism/location Treatment Reagent/analyte/detector/reporter
Data analysis	List-mode data Compensation Gating Descriptive statistics
Instrument details	Instrument identification Fluidics configuration Optical configuration Electronic configuration

To simplify cross-platform comparison and integration, MIFlowCyt is organized in a similar way to minimal information standards from other technological domains.

pliant experiment annotation is provided as Supplementary Material.

MIFlowCyt is explicit in its requirements, following constraint and design recommendations from professional standardization bodies (e.g., www.ietf.org/rfc/rfc2119.txt; <http://standards.ieee.org/guides/style/>). The word *shall* is used to indicate that a particular item is an absolute requirement of the specification. It identifies information that is absolutely crucial in order to allow for interpretation of the experiment. *Shall* combined with *if relevant* indicates information that is not generally applicable but could impact the interpretation of a particular experiment in certain cases. The word *should* is used to indicate that a particular item is recommended but not required. The normative version of this standard is available as Supplemental Information to this manuscript. The key design considerations for MIFlowCyt are described later.

Experiment Overview

An experiment is the evaluation of a set of one or more samples with a specific purpose or objective, such as testing a hypothesis or diagnosing a patient. Information about the overall experiment design shall be provided to understand specific experiment details in the proper context. These details shall include a brief description of the purpose of the experiment and a summary of findings including the interpretation of the results or outcomes. It shall be supported by a list of keywords, preferably from a controlled vocabulary (such as MeSH, www.nlm.nih.gov/mesh/), to facilitate quick orientation and cross-experiment comparison.

If relevant, details shall be provided about experimental variables, i.e., attributes that differ between samples within an experiment due to preexisting differences in sample states

(conditional variables) or experimental manipulation of the samples (manipulated variables), as they are important in understanding the relationship between samples within the experiment (e.g., smoker versus nonsmoker).

Quality control measures (e.g., replicates, calibrations, control assays) shall be described to support comparative statistical evaluation.

Contact information shall be included for further information requests.

Flow Sample/Specimen Description

Description of the sample (or specimen as commonly used in the clinical domain) material and its preparation, treatment, and evaluation are crucial for understanding the experiment. MIFlowCyt specifies three types of samples: biological, environmental, and other samples. For all sample types, a description of the sample shall include information about the nature of the sample material (such as peripheral blood, seawater, or dyed plastic beads). For biological samples, a description of the source shall be provided (e.g., blood as the source of mononuclear cells) and the organism from which they were originally derived shall be identified. Ontologies and/or standardized vocabularies, such as NCBI taxonomy (www.ncbi.nlm.nih.gov/Taxonomy) should be used to facilitate correct interpretation.

Sample treatment descriptions shall specify treatment agents and conditions essential for experiment interpretation or cross-experiment querying, comparisons, and analyses. Access to information about the reagents and how they were used is critical for the correct interpretation of data. Reagents in a FCM experiment are conceptually similar to reagents used in other experiment types: they serve the purpose of measuring analytes and have analyte detector and reporter components. In a FCM experiment, the analyte is often a cell surface protein (e.g., CD25), the analyte detector is often an antibody (e.g., anti-CD25) that specifically binds the analyte, and the reporter is typically a fluorochrome (e.g., FITC).

A description of the entity(ies), disposition(s), or process(es) being evaluated (e.g., CD25, apoptosis, membrane permeability) shall be provided whenever there is ambiguity about the analyte that is being measured by the reagent. For example, if propidium iodide (PI) is added to permeabilized cells, it binds to DNA and thus measures DNA content (e.g., for the evaluation of cell cycle status). When PI is added to nonpermeabilized cells, it is taken up selectively by membrane-compromised cells and is thus an indicator of membrane integrity and cell viability. This is an example of a single reagent measuring different attributes depending on the conditions used for the preparation of the experiment sample, which illustrates the importance of capturing these details.

Instrument Details

Flow cytometers generally consist of three major subsystems: fluidic, optical, and electronic. Flow cytometers operate by passing a sample-containing fluid stream through a beam of light of a specific wavelength. The scattered and emitted fluorescent light is then collected and transformed to electrical

signals, involving a combination of optical and electronic components such as lenses, filters, mirrors, beam splitters, and detectors. The instrument and its configuration and settings directly affect the resulting data. Therefore, it is essential to capture detailed descriptions of selected components of cytometer subsystems in order to properly interpret experimental results.

The instrument manufacturer and model number shall be sufficient if these uniquely specify the required instrument components. Details listed in this section are only required for user-configurable components and cases in which the make and model number are not sufficient to identify the required information. Providing all of the required instrumentation details for configurable components may seem tedious however, most of these are expected to be provided by instrument manufactures and the instruments themselves.

The fundamental information linking sample characteristics to data includes excitation wavelengths of light sources and wavelengths passed by each of the filters. However, it has been demonstrated that other details are also critical (8,9), for example, fluorochrome excitation depends on laser power, material degradation over time influences the performance of optical filters, photomultiplier tube gain highly depends on voltage settings. The amount of light, polarization, and the beam size where the particle is interrogated depend significantly on the optics used to transmit the light from its source to the flow cell component of the fluidics subsystem. The amount of light reaching the flow cell is dependent on the number of optical surfaces involved, the optical coatings used, and the efficiency of any optical fibers used. Thus, the type of flow cell shall be specified as it can affect sensitivity by impacting the background and laser power requirements (10). Specification of the full optical path shall include specification of the light source(s) and the enumeration of all optical components (e.g., optical filters, beam splitters, mirrors), shall specify the detector used and shall state the characteristic of the signal (e.g., height, width, area) that is being digitalized into the parameter value.

Data Analysis

A fundamental principle guiding the publication of scientific results is that supporting data must be made available in a form that allows for independent evaluation of the conclusions as reflected in the data and materials availability policies in most journals (11,12). A common raw data output of a FCM experiment is a list-mode data file, e.g., FCS (4). Ideally, a list-mode data file contains the set of measured parameters (e.g., fluorescence intensities) for each event (e.g., a cell) collected in the sample. These data are crucial for independent reanalysis, and, therefore, either they shall be provided directly or the details shall be stated on how they may be requested.

Fluorescence compensation is a data transformation process used to subtract the fluorescence signal due to one fluorochrome from the fluorescence signal due to another fluorochrome when the fluorochromes have overlapping emissions spectra. Compensation can be performed after signal detection but before digitalization (“hardware compensation”), or after

the data have been collected (“software compensation”). Mathematically, compensation is a straightforward application of linear algebra describable by a compensation matrix, which is often part of the FCS data files. The type of compensation shall be described (e.g., no compensation, hardware compensation, computed compensation) and the spillover or compensation matrix shall be provided whenever available.

Typically, FCM data are analyzed in the context of gates. Gating is a data-filtering process by which populations of events are defined based on parameter value subset combinations. Gating descriptions shall be clear and unambiguous, preferably by mathematical descriptions of each gate boundary. It is important to define qualitative gate descriptors as well as to state denominators used to calculate percentages of events within a gate. The overall gating strategy shall be traceable up to the set of all events.

DISCUSSION

The importance of minimal data reporting standards is illustrated by both community-driven standards such as MIAME (13), MIRIAM (14), MISFISHIE (15), and the CONSORT checklist (16), and cross-community efforts including MIBBI (5), FuGE (6), and OBI (7). MIFlowCyt fills a recognized gap in biomedical data reporting standards by outlining the minimum information required to interpret FCM experiments, understand the conclusions reached, and make comparisons to experiments performed by different laboratories. Nebulous standards and guidelines lead to alternative interpretations resulting in nonuniform, inconsistent reporting (17). MIFlowCyt follows the minimal specification design and overall goals as specified by MIBBI, and it clearly and explicitly identifies the minimum required information for reporting FCM experiments. It communicates the minimum threshold for data exchange and study interpretation, enumerating all of the items required to be reported and the depth of required details. Through MIBBI, MIFlowCyt also aims to contribute to the development of a shared checklist focused on the common experiment components shared among all communities.

MIFlowCyt represents the first crucial step in our efforts to develop universal solutions for representing, collecting, annotating, archiving, analyzing, and disseminating FCM data. Such a minimum information standard sets the stage for the integration of data repositories and data analysis tools. MIFlowCyt describes the minimum information content required to interpret a FCM experiment, independent of the form of how the information is provided. While specification of the form (i.e., data formats) is also essential to facilitate accurate exchange and reuse of experiment data and development of new analytical tools (17,18), these needs are being addressed through separate, coordinated efforts (19,20). For example, a specification for the provision of gating details in XML has been accepted by ISAC's DSTF for consideration as the basis for an eventual standard (<http://flowcyt.sourceforge.net>). Adoption of MIFlowCyt and related standards by Laboratory Information Management Systems (LIMS) would ensure effective interoperability between investigators and other software applications.

The development of MIFlowCyt has been coordinated with submission of applicable FCM-specific terms into OBI and other related ontologies, enabling the potential for structured queries and automated data analysis. Through FICCS (Flow Informatics and Computational Cytometry Society; www.ficcs.org), coordinated efforts have been initiated to develop a data model based on MIFlowCyt by extending FuGE. Publicly available FCM data files are commonly attached as supplementary materials to publications—an unreliable method that does not preserve the data files (17). Therefore, as MIAME guidelines led to expansion of public microarray data repositories such as ArrayExpress (www.ebi.ac.uk/arrayexpress) and GEO (www.ncbi.nlm.nih.gov/geo), we expect MIFlowCyt to influence FCM in a similar way. For example, the Immunology Database and Analysis Portal (www.immport.org) has adopted the MIFlowCyt framework for the capture of FCM data from investigators funded by the Division of Allergy, Immunology, and Transplantation of the NIAID. In addition, efforts are underway under the auspices of ISAC to develop a public data repository for FCM data based on MIFlowCyt.

MIFlowCyt is an ISAC standard stating the minimum information required to report FCM experiments. The normative version of this standard and an example of a MIFlowCyt-compliant experiment annotation are available as Supplemental Information to this manuscript and from www.isac-net.org/, <http://flowcyt.sourceforge.net/>, and <http://mibbi.sourceforge.net/>. Broad adoption of MIFlowCyt by research scientists, clinicians, instrument manufacturers, software developers, and publishers will foster scientific collaboration. It will preserve the integrity and quality of FCM data, which will significantly contribute to the advancement of biomedical sciences by enabling scientists to build upon previous findings.

ACKNOWLEDGMENTS

R.R.B. is a Michael Smith Foundation for Health Research Scholar and an ISAC Scholar. The authors thank the International Society for the Advancement of Cytometry, the Flow Informatics and Computational Cytometry Society, and the Data Interoperability Steering Committee of the Division of Allergy, Immunology, and Transplantation within the National Institute of Allergy and Infectious Diseases for their support and contribution to this effort. The authors also thank James Wood for chairing the ISAC adoption process.

LITERATURE CITED

- Gasparetto M, Gentry T, Sebt S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. *J Immunol Methods* 2004;292:59–71.
- Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, Hayes P, Birungi J, Anzala O, Garcia M, Harari A, Frank I, Baydo R, Baker M, Holbrook J, Ottinger J, Lamoreaux L, Epling CL, Sinclair E, Suni MA, Punt K, Calarota S, El-Bahi S, Alter G, Maila H, Kuta E, Cox J, Gray C, Altfeld M, Nougarede N, Boyer J, Tussey L, Tobery T, Brecht B, Roederer M, Koup R, Maino VC, Weinhold K, Pantaleo G, Gilmour J, Horton H, Sekaly RP. Standardization of cytokine flow cytometry assays. *BMC Immunol* 2005;6:13.
- Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR. Interpreting flow cytometry data: A guide for the perplexed. *Nat Immunol* 2006;7:681–685.
- Seamer LC, Bagwell CB, Barden L, Redelman D, Salzman GC, Wood JC, Murphy RE. Proposed new data file standard for flow cytometry, version FCS 3.0. *Cytometry* 1997;28:118–122.
- Taylor CE, Field D, Sansone S-A, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz P-A, Bogue M, Booth T, Brazma A, Brinkman RR, Clark AM, Deutsch EW, Fiehn O, Fostel J, Ghazal P, Gibson F, Gray T, Grimes G, Hardy NW, Hermjakob H, Julian Jr RK, Kane M, Kettner C, Kinsinger C, Kolker E, Kuiper M, Le Novère N, Leebens-Mack J, Lewis SE, Lord P, Mallon A-M, Marthandan N, Masuya H, McNally R, Mehrle A, Morrison N, Quackenbush J, Reecy JM, Robertson DG, Rocca-Serra P, Rodriguez H, Santoyo-Lopez J, Scheuermann RH, Schober D, Smith B, Snape J, Tipton K, Sterk P, Wiemann S. Promoting coherent minimum reporting requirements for biological and biomedical investigations: The MIBBI project. *Nat Biotechnol* 2008;26:889–896.
- Jones AR, Miller M, Aebersold R, Apweiler R, Ball CA, Brazma A, Degreiff J, Hardy N, Hermjakob H, Hubbard SJ, Hussey P, Igra M, Jenkins H, Julian Jr RK, Laursen K, Oliver SG, Paton NW, Sansone SA, Sarkans U, Stoekert Jr CJ, Taylor CE, Whetzel PL, White JA, Spellman P, Pizarro A. The Functional Genomics Experiment model (FuGE): An extensible framework for standards in functional genomics. *Nat Biotechnol* 2007;25:1127–1133.
- Whetzel PL, Brinkman RR, Causton HC, Fan L, Field D, Fostel J, Fragoso G, Gray T, Heiskanen M, Hernandez-Boussard T, Morrison N, Parkinson H, Rocca-Serra P, Sansone SA, Schober D, Smith B, Stevens R, Stoekert CJ Jr, Taylor C, White J, Wood A. Development of FuGO: An ontology for functional genomics investigations. *OMICS* 2006;10:199–204.
- Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. *J Immunol Methods* 2000;243:77–97.
- Shapiro HM. 8 Buying flow cytometers, 9 building flow cytometers. In: Doe JA, Doe B, Doe CD, editors. *Practical Flow Cytometry*, 4th ed. Hoboken, NJ: John Wiley & Sons; 2003. pp 411–442.
- Shapiro HM. 4.6 How flow cytometers work—Flow systems. In: Doe JA, Doe B, Doe CD, editors. *Practical Flow Cytometry*, 4th ed. Hoboken, NJ: John Wiley & Sons; 2006. pp 166–180.
- Ball CA, Brazma A, Causton H, Chervitz S, Edgar R, Hingamp P, Matese JC, Parkinson H, Quackenbush J, Ringwald M, Sansone S-A, Sherlock G, Spellman P, Stoekert C, Tatenio Y, Taylor R, White J, Winegarden N. Submission of microarray data to public repositories. *PLoS Biol* 2004;2:E317.
- Bourne P. Will a biological database be different from a biological journal? *PLoS Comput Biol* 2005;1:179–181.
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoekert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisio P, Holstege FC, Kim IE, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)—Toward standards for microarray data. *Nat Genet* 2001;29:365–371.
- Le Novère N, Finney A, Hucka M, Bhalla US, Campagne F, Collado-Vides J, Crampin EJ, Halstead M, Klipp E, Mendes P, Nielsen P, Sauro H, Shapiro B, Snoep JL, Spence HD, Wanner BL. Minimum information requested in the annotation of biochemical models (MIRIAM). *Nat Biotechnol* 2005;23:1509–1515.
- Deutsch EW, Ball CA, Bova GS, Brazma A, Bumgarner RE, Campbell D, Causton HC, Christiansen J, Davidson D, Eichner LJ, Goo YA, Grimmond S, Henrich T, Johnson MH, Korb M, Mills JC, Oudes A, Parkinson HE, Pascal LE, Quackenbush J, Ramialison M, Ringwald M, Sansone SA, Sherlock G, Stoekert Jr CJ, Swedlow J, Taylor RC, Walashek L, Zhou Y, Liu AY, True LD. Development of the minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). *OMICS* 2006;10:205–208.
- Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust* 2006;185:263–267.
- Burgoom LD. The need for standards, not guidelines, in biological data reporting and sharing. *Nat Biotechnol* 2006;24:1369–1373.
- Quackenbush J. Data standards for 'omic' science. *Nat Biotechnol* 2004;22:613–614.
- Spidlen J, Gentleman RC, Haaland PD, Langille M, Le Meur N, Ochs ME, Schmitt C, Smith CA, Treister AS, Brinkman RR. Data standards for flow cytometry. *OMICS* 2006;10:209–214.
- Leif RC. CytometryML, a data standard, which has been designed to interface with other standards. In: Farkas DL, Leif RC, Nicolau DV. *Imaging, manipulation and analysis of biomolecules, cells and tissues*, V. 2007; *Proc of SPIE*, vol 6441: doi: 10.1117/12.699617.